July 27, 2015
News & Features
A family says a drug company led them to believe that their 16-year-old son could participate in a clinical trial for an experimental muscular dystrophy drug, but then went back on its word.
It is a case that pits a mother desperately seeking a medical treatment for her son against a biotechnology company for whom she claims to have worked tirelessly as an advocate.
A growing band of researchers is trying to redefine how diseases are classified — by looking at their genetic underpinnings.
After years of futile attempts at replacing the defective gene that causes Duchenne muscular dystrophy, researchers are now more intent on overriding the gene.
Rather than concentrate only on a cure for a common form of muscular dystrophy, researchers are now intent on alleviating its effects.
Researchers in the Netherlands have developed a drug that may eventually be used to treat children with a severe and fatal type of muscular dystrophy.
Genealogy often holds the key to understanding the origin of serious diseases in those with a Hispanic heritage.
The X chromosome does much more than help specify an animal’s reproductive plumbing and behaves unlike any of the other chromosomes in the body.
Mounting evidence is suggesting that as men get older, they face an increased risk of fathering children with abnormalities.
Thomas H. Murray, president of the Hastings Center, a bioethics research group in Garrison, N.Y., spends a large part of his day considering the culture, philosophy and ethics of the sporting world. As the author of several papers on the use of science in sports, Dr. Murray, a social...
MOST POPULAR - HEALTH
- Well: How Walking in Nature Changes the Brain
- Well: Snoring Children May Suffer From Sleep Apnea
- Well: Cool at 13, Adrift at 23
- Well: Rethinking Exercise as a Source of Immediate Rewards
- Well: Screen Addiction Is Taking a Toll on Children
- Well: A 2-Minute Walk May Counter the Harms of Sitting
- Benefit of End-Stage Chemotherapy Is Questioned
- Fetal Tissue From Abortions for Research Is Traded in a Gray Zone
- Well: When Cancer Triggers (or Hides) an Eating Disorder
- Praluent Looks Cheap to Those With Extreme Cholesterol